3 hours ago
CRISPR Therapeutics (CRSP) Stock Plunges 11% Amid Earnings Disappointment and Competitive Threat
CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds pressure on Casgevy pricing.
The post CRISPR Therapeutics (CRSP) Stock Plunges 11% Amid Earnings Disappointment and Competitive Threat appeared first on Blockonomi.
Source: Blockonomi →Related News
- 3 hours ago
Advanced Micro Devices (AMD) vs Intel (INTC): Top Chip Stock for 2025
- 3 hours ago
Nvidia (NVDA) Surges to Record High, Market Cap Surpasses $5 Trillion Milestone
- 3 hours ago
Palantir (PLTR) Stock Plunges 20% in 2026 — Analysts Signal Strong Buy Opportuni...
- 3 hours ago
Palantir (PLTR) Stock Plunges 20% YTD — Analysts See Major Rebound Potential
- 3 hours ago
AMD Stock Soars 14% Following Intel’s Strong Earnings and D.A. Davidson Upgrade